相关临床试验
0
0 进行中
药物批准
2
批准总数
监管机构
1
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
- Biocon Biologics and Civica announced an expanded partnership to launch a private-label insulin glargine product, providing additional treatment options for 38.4 million Americans living with diabetes. - The multi-year agreement establishes an exclusive distributorship where Biocon Biologics will manufacture and supply insulin glargine to Civica for commercialization under separate Civica and CalRx labels. - This collaboration builds on the companies' existing relationship and leverages Biocon Biologics' FDA-approved interchangeable biosimilar insulin glargine-yfgn to expand access to affordable diabetes treatments. - The partnership aims to reach underserved populations through new distribution channels while maintaining Biocon Biologics' direct commercialization of its own insulin glargine product.
• Biocon Biologics will supply Insulin Aspart drug substance to Civica, who will manufacture the final product at their Virginia facility to increase accessibility in the United States. • The partnership aims to address a critical healthcare need, as one in five diabetes patients has rationed insulin due to cost concerns, in a country where 38.4 million people live with diabetes. • The collaboration runs parallel to Biocon Biologics' own Insulin Aspart product currently under FDA review, demonstrating the company's multi-pronged approach to expanding insulin accessibility.
